zantac-75 and Dasatinib Interactions

Interactions between zantac-75(ranitidine) and Dasatinib (dasatinib)

ranitidine and dasatinib (Moderate Drug-Drug)

GENERALLY AVOID: Nonclinical data indicate that the solubility of dasatinib is pH-dependent. Therefore, long-term suppression of gastric acid secretion by H2-receptor antagonists or proton pump inhibitors is likely to reduce dasatinib systemic exposure. In a pharmacokinetic study of 24 healthy subjects, administration of a 50 mg dose of dasatinib 10 hours after famotidine was associated with a 61% reduction in systemic exposure (AUC) and a 63% reduction in peak plasma concentration (Cmax) of dasatinib.

MANAGEMENT: The concomitant use of H2-receptor antagonists or proton pump inhibitors with dasatinib is not recommended. If gastric acidity management is necessary, antacids should be considered in place of these agents. However, patients treated with dasatinib should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and two hours after administration of dasatinib.